The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Additionally, the guidelines recommend that 1 mg of glucagon be administered after a prolonged fast or a mixed meal, as this will distinguish hypoglycemia caused by endogenous or exogenous insulin ...

and this effect is accentuated in postsurgical patients who develop recurrent hypoglycemia. Plasma levels of the incretin glucagon-like peptide 1 (GLP-1) are dramatically increased after GB ...